Tina Nova

Dr. Nova has extensive experience growing dynamic commercial organizations in new markets within the molecular diagnostics field. She currently serves as president and chief executive officer of Decipher Biosciences, Inc., a diagnostics company focused on urologic cancers, since August 2018, and previously was president and chief executive officer of Molecular Stethoscope, Inc., and served as senior vice president and general manager of Illumina’s oncology business unit.

Dr. Nova was a co-founder of Genoptix, a medical laboratory diagnostics company, and served as its president and chief executive officer from 2000 to 2014. Genoptix was acquired by Novartis AG in 2011. Dr. Nova was co-founder of Nanogen, a provider of molecular diagnostic tests, and served as its chief operating officer and president from 1994 to 2000. She previously served as chief operating officer of Selective Genetics, a biotechnology company, and held various positions with Ligand Pharmaceuticals and Hybritech.

Dr. Nova serves as the chair of the board of directors for Arena Pharmaceuticals and as a member of the board of directors of Veracyte, a diagnostics company. Dr. Nova received a bachelor’s degree in biological sciences from the University of California, Irvine, and a doctorate in biochemistry from the University of California, Riverside.